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Abstract 
 
ESAC, the EURL ECVAM Scientific Advisory Committee, advises EURL ECVAM on scientific 
issues. Its main role is to conduct independent peer review of validation studies of 
alternative test methods and to assess their scientific validity for a given purpose. The 
committee reviews the appropriateness of study design and management, the quality of 
results obtained and the plausibility of the conclusions drawn. ESAC peer reviews are 
formally initiated with a EURL ECVAM Request for ESAC Advice, which provides the 
necessary background for the peer-review and establishes its objectives, timelines and the 
questions to be addressed. The peer review is normally prepared by specialised ESAC 
Working Groups. ESAC's advice to EURL ECVAM is formally provided as 'ESAC Opinions' and 
'Working Group Reports' at the end of the peer review. ESAC may also issue Opinions on 
other scientific issues of relevance to the work and mission of EURL ECVAM but not directly 
related to a specific alternative test method.   
The ESAC Opinion expressed in this report relates to the peer-review of the Bioelution in 
vitro test method. 
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Ispra, 2 December 2019 
ESAC Opinion 
 
In March 2019, the EURL ECVAM Scientific Advisory Committee (ESAC) (Annex 1) was 
formally asked by EURL ECVAM to review the available proof of the scientific validity of the 
Bioelution test method to assess the relative in vitro bioaccessibility (IVBA) of metals and 
metalloids in inorganic metal compounds and metal (metalloid)-containing materials as 
compared to reference materials using a simulated gastric fluid. An ESAC Working Group 
(WG) was established for this purpose (Annex 1), which delivered an ESAC WG report (Annex 
2) to support the development of this opinion. The analysis and conclusions of the ESAC WG 
were based primarily on the Bioelution test method files submitted to EURL ECVAM, 
including all the relevant study Annexes and supporting documents. The assessment also 
included direct requests from the ESAC WG to the test method submitter for supporting 
information. 
At its 46th meeting, held on 2-3 December 2019 at EURL ECVAM, Ispra, Italy, the non-
Commission members of ESAC unanimously endorsed this opinion. 
The Bioelution test method generates relative IVBA data that can be used to (i) support 
grouping and read across of inorganic metal compounds and metal (metalloid)-containing 
materials (e.g. UVCBs, pigments and alloys) and (ii) establish the presence or absence of a 
matrix effect to inform alloy classification based on the relative bioaccessible concentration 
(%RBC) of a metal in an alloy versus a reference material (e.g. a pure metal). 
To assess the scientific validity of the Bioelution test method, the ESAC evaluated the 
biological relevance of the method, the relevance of the measurement of %RBC, the 
robustness of the protocol and the reproducibility of the %RBC measurement. 
Based on the available information, the existing scientific literature and the experts' own 
extensive experience as detailed in the ESAC WG report, the ESAC unanimously concluded 
the following: 
The Bioelution test method is biologically relevant 
In vivo oral bioavailability refers to the fraction of the total amount of a substance that 
is released in the gastrointestinal tract and absorbed into the blood stream. This can be 
estimated in vitro by measuring the dissolved quantity of a metal ion release under 
surrogate physiological conditions in a bioaccessibility test. IVBA testing is a well-
established approach in use for several years. Bioaccessibility tests for the oral route of 
exposure (including gastric compartment) have been applied to the assessments of human 
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exposures to metal compounds and minerals in soils and dust. US EPA Validated Test 
Method 1340 assesses the bioaccessibility for lead (Pb) in soil. Validation studies of IVBA 
test methods for estimation of bioavailability of arsenic (As) from soil and sediment have 
been conducted. Moreover, the proposed Bioelution test method is similar to the 
Bioaccessibility Research Group of Europe (BARGE) test method, which has been in use in 
Europe for several years to assess As, Pb, Antimony (Sb) and Cadmium (Cd) in soil samples 
and was accepted as an ISO standard in 2018 (ISO 17924). 
The Bioelution test method is representative of the gastric compartment. Publications in 
the peer-reviewed literature show that additional components (e.g., ascorbic acid, pepsin, 
and glycine) could be added to the gastric solution to increase solubility of certain metals 
(e.g., Whitacre et al. 2017). However, these additional components add complexity to the 
method and are unlikely to affect the relative measurement that the method produces. The 
selection of the 2-hour extraction time is consistent with other IVBA methods using 
simulated gastric fluid and with the time for complete emptying of the human stomach. 
The ESAC supports the current Bioelution test method protocol and acknowledges that the 
simple gastric solution is fit-for-purpose considering the proposed context of use. 
A comparison of the IVBA data with in vivo oral relative bioavailability data was not 
conducted in this ESAC review. Relative bioavailability is the ratio of the oral absorption 
fraction of the chemical present in some target material to the oral absorption fraction of 
the chemical in an appropriate reference material. It accounts for differences in absorption 
between the chemical in the reference material and in the test material. Such comparison is 
not necessary and does not compromise the assessment of the scientific validity of the 
method given that relative measurements between target and reference materials are used 
both for grouping and read across, and classification of alloys. 
The Bioelution test method is appropriate to assess if a matrix effect occurs in 
alloys 
The Bioelution test method can be used to assess the matrix effect of an alloy by 
comparing the release of metal ions between a reference material (e.g. pure metal) and an 
alloy. When a matrix effect occurs, there is an increased or decreased relative release of 
the metal ions from the alloy in comparison to the reference material. In the absence of a 
matrix effect (e.g. simple metal mixture), a linear relationship between the fraction of metal 
ion release and the total content of that metal in the material is expected and this has 
been confirmed by the method developers. Therefore, the ESAC considers that this is an 
appropriate use of the Bioelution test method. 
The Bioelution test method is a simple, reproducible approach and is applicable to 
many metals 
The ESAC considers that the within- and between-laboratory reproducibility of absolute 
bioaccessibility measurements for the six metals tested (i.e. Co, Cu, Fe, Ni Pb, Zn tested in 
the round robin trial as published by Henderson et al., 2014) were acceptable. The ESAC 
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considers that this should hold true also for other metals; however, data have not been 
provided to support this assumption. The current standard operating procedures (SOP) 
further ensures reproducibility across laboratories by ensuring high consistency in the 
preparation of the simulated gastric fluid. Reproducibility and international harmonisation 
are also ensured by clearly defining the reference materials for each metal that must be 
run in parallel to test materials for alloy classification purposes. While for the read across 
and grouping application it is not possible to predefine the reference materials, the SOP still 
requires these to be run concurrently to the target material so as to guarantee the 
robustness and consistency of the relative measurement. The applicability domain is clearly 
described in the SOP in terms of technical limitations and context of use and is considered 
appropriate. In conclusion, the ESAC considers that the SOP is well described and robust, 
thus ensuring reproducibility of data and easy implementation of the assay by naïve 
laboratories. 
Conclusion and Recommendation 
The ESAC concludes that the Bioelution test method is scientifically valid for 
determining the relative IVBA of metals and metalloids in inorganic metal 
compounds and metal (metalloid)-containing materials to be used in the context 
of their classification. Thus, the ESAC recommends that the Bioelution test 
method progresses to Test Guideline development at OECD level to achieve 
international harmonisation. 
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ESAC Working Group 
 
Full title: ESAC Working Group on the Bioelution Test Method  
 
Abbreviated title:  ESAC WG Bioelution 
 
The ESAC WG was established in April 2019 by written procedure to assist in the production of an 
ESAC Opinion on the scientific validity of the Bioelution test method to assess the relative in vitro 
bioaccessibility (IVBA) of metals and metalloids in inorganic metal compounds and complex metal 
(metalloid)-containing materials using a simulated gastric fluid.  
This report was prepared at the request of EURL ECVAM by the "ESAC Working Group Bioelution" 
(ESAC WG), which was charged with conducting a detailed scientific peer review of the Bioelution 
test method. The basis for the scientific peer review was the EURL ECVAM Request for ESAC Advice 
approved by the ESAC by written procedure following the ESAC44 plenary meeting of December 
2018 (ESAC request 2019-01). 
The ESAC WG met at EURL ECVAM on 02-03/05/2019 and 25-26/09/2019 to conduct its peer 
review. This ESAC WG Report was endorsed by the ESAC WG on 26/02/2020 and represents its 
consensus view. The Report was endorsed by the ESAC on 13/03/2020. 
 
The ESAC WG had the following members: 
• Dr. Chantra ESKES (ESAC Core Member, WG Chair) 
• Prof. Emanuela CORSINI (ESAC Core Member) 
• Prof. Annette KOPP-SCHNEIDER (ESAC Core Member) 
• Dr. Valerie HANLEY (ESAC Ad-hoc Member) 
• Prof. Irina KARADJOVA (ESAC Ad-hoc Member) 
• Dr. Mina SUH (ESAC Ad-hoc Member, WG Rapporteur) 
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1. Study objective and design 
1.1 Analysis of the clarity of the study objective's definition 
(a) ESAC WG summary of the study objective as outlined in the Test Submission 
The Bioelution method is proposed to generate relative bioaccessibility data by comparing the in 
vitro metal ion releases from target and reference material in simulated gastric fluid for the oral 
route of exposure. 
In 2016, EURL ECVAM received a pre-submission of the Bioelution method by the test submitter, 
which led to launch of a consultation within the PARERE network. On the basis of the evaluation of 
the pre-submission and feedback received from the PARERE members, EURL ECVAM invited the test 
submitter to submit a full submission and provide clarifications and detailed information to address 
the comments from PARERE and EURL ECVAM. In 2018, EURL ECVAM received the full submission 
of the Bioelution method for testing of metals, inorganic metal compounds, and complex metal-
containing materials in simulated gastric fluid.  
The ESAC WG was formed and met in May and September 2019. Several teleconferences were also 
held between October 2019 and February 2020. The ESAC WG was requested to review the 
available proof of the scientific validity of the Bioelution method to assess relative bioaccessibility 
of metals in inorganic metal compounds and metal-containing materials as compared to reference 
materials. 
The ESAC WG was asked by EURL ECVAM to deliberate on the following issues concerning the 
Bioelution method:  
1) The number and quality of the test items used in view of the study objectives;  
2) The reliability (reproducibility within and between laboratories) of the results obtained in 
vitro; 
3) The biological relevance with regard to the in vitro system and experimental conditions used 
as being:  
a. Representative of the gastric compartment,  
b. Worst case scenario for the oral route of exposure, 
c. Relevant in relation to the dermal and inhalation routes of exposure; 
4) Appropriateness of identification of applicability and limitations of the method; 
5) The relationship between in vitro bioaccessibility (IVBA) in simulated gastric fluids and 
relative in vivo bioavailability (e.g. from contaminated soil studies) and its relevance in the 
context of the two regulatory applications proposed (1-grouping and read across and 2- 
establish the presence or absence of a matrix effect to inform alloy classification); 
6) Appropriateness of the relative measurements of  bioaccessibility between pure metal and 
alloy used to calculate the relative bioaccessible concentration (%RBC) to show metal 
releases affected by matrix effects; 
7) Appropriateness of the experiments carried out to demonstrate that there is a linear 
relationship between the fraction of metal ion release in the absence of a matrix effect 
(simple mixture) and the total content of that metal in the material; 
8) Clarity and completeness of the protocol and the prediction model; 
9) The readiness of the method for regulatory use.  
 
(b) Appraisal of clarity of study objective as outlined in the Test Submission 
The ESAC WG agrees that the study aimed to demonstrate the reproducibility and robustness of the 
proposed protocol to assess the relative IVBA  of metals, inorganic metal compounds, and complex 
metal-containing materials using a simulated gastric fluid.  
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1.2 Quality of the background provided concerning the purpose of the test 
method  
The ESAC WG is of the understanding that the objective of the test method is not to predict the 
actual in vivo bioavailability values, but rather to allow comparisons of bioaccessibility of a given 
metal between target and reference materials. 
The relative IVBA generated by the Bioelution method can be used to i) support grouping and read 
across and ii) establish the presence or absence of a matrix effect to inform alloy classification. 
Under grouping and read across, relative IVBA data may be used, in a weight-of-evidence (WoE) 
approach, to support grouping and read across of metal-containing substances and mixtures. Under 
alloy classification, IVBA data may be used to calculate the %RBC of a metal ingredient in an alloy, 
which is compared to its bulk concentration. 
The ESAC WG considers that the information provided is of sufficient quality to evaluate this 
context of use. 
 
(a) Analysis of the scientific rationale provided in the Test Submission 
The systemic toxicity of most metals and metalloids is associated with the release of metal ions 
and their uptake by the body and/or interaction at their target organ sites (i.e., bioavailability). The 
bioavailability of the released metal at the site of action in the organism is relevant for determining 
toxicity of metals and minerals. Currently, there are many relative IVBA methods that evaluated 
metal releases in simulated gastric fluid from various materials. These methods have been tested 
in soils (e.g. ASTM D5517 2007; BS EN71-3 2013; BARGE UBM 2016). However, there are no 
internationally recognized (e.g. EU or OECD) bioelution test methods specifically designed to assess 
metal releases relevant to systemic health effects after oral exposure.  
Bioelution method is an in vitro method used to measure metal releases in simulated gastric fluid 
(0.032M HCl, pH 1.5). It does not address a biological effect. Bioelution method provides data 
regarding in vitro estimates of relative bioaccessibility, which is related to systemic bioavailability of 
metal ions. 
The test submission makes sufficient reference to the relevant body of the scientific literature. IVBA 
tests for the oral route of exposure (including gastric compartment) have been applied to the 
assessments of human exposures to metal compounds and minerals in soils and dust (e.g. Ruby et 
al. 1999, Suh et al. 2019, Whitacre et al. 2017, Wragg et al. 2011). USEPA Validated Test Method 
1340 (one of SW-846 guidance methods) assesses the bioaccessibility assay for lead (Pb) in soil. 
Validation of an In Vitro Bioaccessibility Test Method for Estimation of Bioavailability of Arsenic 
from Soil and Sediment has been conducted (ESTCP Project ER-200916 2012; Brattin et al. 2013). 
Moreover, the proposed Bioelution method is similar to the Bioaccessibility Research Group of 
Europe (BARGE) method, which has been in use in Europe for several years to assess arsenic (As), 
Pb, antimony (Sb) and cadmium (Cd) in soil samples and was accepted as an ISO standard in 2018 
(ISO 17924). 
 
(b) Analysis of the regulatory rationale provided in the Test Submission 
The relative IVBA data generated by the Bioelution method can be used to i) support grouping and 
read across and ii) establish the presence or absence of a matrix effect to inform alloy 
classification. Under grouping and read across, relative IVBA data may be used to group metal 
compounds or metal-containing materials that release similar amounts of metal ion and to use this 
information in a WoE approach to read across oral systemic effects. Under alloy classification, 
the %RBC of the metal ion between the alloy and the pure metal ingredient is calculated and 
compared to the bulk concentration of that metal ingredient in the alloy in order to assess the 
presence of a matrix effect.  
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The ESAC WG is of the understanding, however, that while the Bioelution method addresses the 
generation of IVBA in simulated gastric fluid and its use for the calculation of %RBC of metals in 
alloys, it is not to be used to predict relative bioavailability values for application in a risk 
assessment context without further evaluation.   
The application of the Bioelution assay in a regulatory context is not part of the present  
assessment. 
 
1.3 Appraisal of the appropriateness of the study design 
Henderson et al., 2014 Round Robin study 
Number of laboratories: Five laboratories were used for the round robin trial (RRT), and the 
results were published in Henderson et al. (2014).   
Organisation of study: The method validation study was initiated in 2010 by a group of 
representatives from various metal commodities seeking to standardize fluid compositions and 
testing protocols for the basic bioelution methods being used across the industry. To investigate the 
within-laboratory repeatability and between-laboratory reproducibility of bioaccessibility testing in 
different simulated fluids (including gastric fluid), five laboratories measured metal release from six 
metal-containing materials following one defined protocol (standard operating procedure, SOP) 
issued by the study sponsors. The study was funded by five commodity groups, with each 
organization having a key point person that participated in steering team and technical discussions 
(Henderson et al., 2014).  
Chemical selection: Six different metals and metal-containing materials following the SOP were 
evaluated in the RRT. These test items represent water soluble metal compounds, insoluble metal 
compounds, pure metals, and complex materials (alloys and ore concentrates). They cover the 
various types of metals and materials the proposed test method is intended to be applied to. They 
also represent a variety of physicochemical properties that impact the metal releases. Samples of 
each of the six materials (pre-characterized for particle size, metal content, and surface area) were 
distributed to each of the five laboratories from two independent repositories (Particle Technologies 
Laboratory (Downers Grove, IL, USA) and Outotec (Finland)). Given the nature of the test materials 
and the bulk metal content, the procedure for chemical selection was deemed appropriate by the 
ESAC WG.   
Quality Assurance (QA) of data: Each laboratory generated a comprehensive report, which 
underwent a QA exercise. A detailed review and comparison between the SOP and the five 
laboratory reports was performed. An external inter-laboratory comparison was conducted to 
investigate the within-laboratory repeatability and between-laboratory reproducibility of 
bioaccessibility testing in different simulated fluids, including gastric fluid. The outcome of the 
study was published in Henderson et al. (2014). The QA of the gastric fluid data was evaluated by 
the ESAC WG and considered appropriate.  
Statistical independence: The statistical analysis was conducted by two independent 
biostatisticians.  
 
Additional studies provided 
Appendix 1 provides a detailed list of all additional studies that have been provided to the ESAC WG 
between 2017 and 2019. These additional studies included data to demonstrate calculations of 
%RBC and evaluation of matrix effect. The test submitter included data on the metal ion release in 
the absence of a matrix effect (simple mixture) versus metal ion release in the presence of matrix 
effect (metal alloy) for various metals and metal-containing compounds. The data also included 
comparisons of the different methods used to prepare the gastric fluid as well as showing the 
proof-of-concept for the SOP. Additionally, reproducibility of %RBC values was also demonstrated. 
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1.4 Appropriateness of the statistical evaluation 
Two independent statistical analyses were conducted. One was based on the international standard 
ISO 5725-2 [Accuracy (Trueness and Precision) of Measurement Methods and Results-Part 2: Basic 
method for the determination of repeatability and reproducibility of a standard measurement 
method, 1994] and used Mandel's k and h statistics to evaluate within- and between laboratory 
consistency, respectively.  Cochran test and Grubbs test were used to identify outliers during the 
analysis of within - and between laboratory consistency, respectively.  
The second approach used to assess within- and between-laboratory reproducibility was based on 
the relative standard deviation (RSD) analysis of the log concentration and was expressed in 
percentages. RSD < 10% was the criteria used for acceptable repeatability and RSD < 20% for 
acceptable laboratory-to-laboratory variability. Repeatability standard deviation (Sr; within-
laboratory) and reproducibility standard deviation (SR; between-laboratories) were used as 
measurements of precision. RSD was used to assess the fluctuations in the data relative to the data 
mean. The ratio SR:Sr of the log-concentration was used to compare the mean results of the 
laboratories. Good, fair or poor agreement between laboratories was indicated by ratios up to 3, 
between 3 and 6, and above 6, respectively. 
The statistical approaches used to evaluate within- and between-laboratory reproducibility, 
although different from the traditional ones used in validation studies, follow international 
standards for the determination of repeatability and reproducibility. The ESAC WG considers these 
methods to be appropriate and sufficiently justified. 
 
 
2. Collection of existing data 
2.1 Existing data used as reference data 
The Bioelution method is not to be used for predicting relative bioavailability for application in a risk 
assessment context. As such, the absence of in vivo relative bioavailability data to make a direct 
comparison to relative IVBA data does not compromise the assessment of the scientific validity of 
the method. However, there is evidence that IVBA is a conservative assumption of in vivo 
bioavailability, i.e., higher RBCs than those provided by in vivo data (Whitacre et al. 2017., Suh et al. 
2019). Additionally, the comparative nature of the approach is inherent to both proposed 
applications with relative measures that are being calculated. This provides further support for use 
of the Bioelution method and mitigates the concern that in vivo bioavailability reference data 
associated with the test chemicals are absent.  
As part of the existing information provided to help understand the relationship between IVBA and 
in vivo bioavailability, the submitter provided a review performed by Alloy, LLC (Attachment 18 of 
the submission). This review evaluated 38 peer-reviewed studies (and 1 unpublished study), of 
which 22 contained data for evaluations conducted both in vivo and in vitro and an additional 17 
presented data from in vitro extraction testing of soils. The metals evaluated in these studies 
included Sb, As, Cd, cobalt (Co), Pb, mercury (Hg), and nickel (Ni). This review nicely captures how 
IVBA relates to in vivo bioavailability.  Importantly, the review stresses that the IVBA data may not 
be used directly to predict in vivo relative bioavailability, but rather the equation describing the 
regression line in paired in vivo and in vitro data is used to “translate” IVBA into a prediction of 
relative bioavailability. For the majority of the studies evaluated the slope of the regression 
equation was <1, indicating that the IVBA was higher than the in vivo relative bioavailability and 
that the IVBA is typically a conservative measurement for in vivo relative bioavailability. The review 
further evaluated various components of the simulated gastric fluid used in the various studies and 
discussed that pH was the major determining factor regarding extraction of soluble metals. The 
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Alloy, LLC review was thorough and beneficial among the submission materials reviewed by the 
ESAC WG.   
However, the ESAC WG did not consider Diamond et al., 2016 publication mentioned in the Alloy, 
LLC review as appropriate evidence regarding the uncertainty associated with IVBA/in vivo 
bioavailability correlations. Two flaws were identified in the statistical analysis. First, instead of 
performing a (random-effects) meta-analysis, the authors fitted separate regression models for 
each data set and subsequently evaluated the pooled data in a weighted regression analysis based 
on the fact that the slopes in the separate analyses were not significantly different. Second, even 
more importantly, IVBA data are observed with measurement error and hence can only be used as 
explanatory variable in a regression analysis when an error-in-variables model is applied. The 
consequence of using the standard regression model instead of an error-in-variables model is that 
the estimated slope underestimates the true value. Furthermore, the ESAC WG considers that the 
combination of data from two species (swine and mouse) into a single regression as presented in 
Diamond et al. (2016) is not appropriate.  
 
2.2 Existing data used as testing data 
Several sources were used as the testing data for validation of the Bioelution method including the 
RRT published by Henderson et al. (2014), and the additional studies that were submitted from June 
2017 through October 2019 to ESAC as listed in Appendix 1.  
ESAC WG evaluated all data and information provided by the test submitter and EURL ECVAM. The 
data are pertaining to the Bioelution method, and thus the WG considers them to be appropriate. 
Additionally, in the SOP, the test submitter specify the data pertaining to each metal that are 
applicable to the Bioelution method. 
 
2.3 Search strategy for retrieving existing data 
Not applicable. 
 
2.4 Selection criteria applied to existing data 
No selection criteria were applied to the existing data because all data that have been provided 
were generated and/or sponsored by the test submitter. All data were evaluated and pertained to 
the Bioelution method, and thus the WG considers them to be appropriate. 
 
 
3. Quality aspects relating to data generated during the 
study 
3.1 Quality assurance systems used when generating the data 
The study reports mentioned above specify that the delegated analytic phase has been performed 
according to the criteria of the ISO 17025 standard. Moreover, the study reports indicate that each 
study has been audited by the QA Unit to assure compliance with the study plan, SOPs, and 
according to the OECD Principles of GLP. The ESAC WG endorses the QA measures taken in these 
studies used in support of the Bioelution method. 
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3.2 Quality check of the generated data prior to analysis 
See section 3.1. In-addition to in-house QA procedures, QA checks were performed and presented in 
Henderson et al. (2014) RRT as well as in an independent statistical analysis.  
 
 
4. Quality of data used for the purpose of the study (existing 
and newly generated) 
4.1 Overall quality of the evaluated testing data (newly generated or existing) 
The assessment of within-laboratory reproducibility was done with 6 inorganic metal-containing 
materials, tested in five laboratories, as reported in Henderson et al. (2014). Two independent 
statistical analyses were carried out as described in section 1.4.  
The between-laboratory reproducibility was assessed during the inter-laboratory RRT reported by 
Henderson et al. (2014). The data available in this paper is not very extensive, but the test 
submitter calculated, based on an analysis of coefficients of variation (CVs) and negative control 
values, the percentages of disqualified tests. Furthermore, limits of quantification (LOQs) were not 
reported, but calculated from limits of detection (LODs) as 2xLOD. Out of 43 measurements 5 
(12%) had CVs that did not meet the acceptance criteria. The quality of testing data is therefore 
very high. All laboratories included in testing and validation studies are accredited (Henderson et al. 
2014). Reagents, standards and reference materials used are of very high quality, and the most 
sensitive method Inductively Couple Plasma-Mass Spectrometry (ICP-MS) is used for measurements. 
The ESAC WG considers these data to be acceptable. 
At the request of ESAC WG, the test submitter provided additional studies in form of laboratory 
reports in August 2019 and October 2019 (see Appendix 1). The data were requested by ESAC WG 
to demonstrate that the different methods used to prepare simulated gastric fluid would not 
significantly impact the %RBC, which is based on the metal ion release in the reference material vs. 
metal ion release in the test material, and that %RBC calculations would be reproducible. The 
additional generated data was used as a proof-of-concept for the proposed SOP revisions. The ESAC 
WG determined that data were robust and of sufficient quality for evaluation.   
 
4.2 Quality of the reference data for evaluating relevance1 
Not applicable. See section 2.1. 
 
4.3 Sufficiency of the evaluated data in view of the study objective 
The ESAC WG requested for additional data on the different methods used to prepare the simulated 
gastric fluid and whether the preparation of simulated gastric fluid made any difference in the 
metal ion release and the %RBC calculations. These additional data demonstrated the 
reproducibility of the %RBC calculations based on the different methods used to prepare the 
simulated gastric fluid. The ESAC WG considers the quality of the entire data set sufficient to draw 
robust conclusions. 
 
                                                 
1 OECD guidance document Nr. 34 on validation defines relevance as follows: "Description of relationship of 
the test to the effect of interest and whether it is meaningful and useful for a particular purpose. It is the 
extent to which the test correctly measures or predicts the biological effect of interest. Relevance incorporates 
consideration of accuracy (concordance) of a test method." 
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5. Test definition (Module 1) 
5.1 Quality and completeness of the overall test definition  
The Bioelution method is well-defined as an in vitro physico-chemical test that measures metal 
releases in simulated gastric fluid.  The test provides IVBA of metals and metalloids from a variety 
of materials.  This method is always used to compare a test material to a reference material so the 
output is always a relative measurement. 
The test system is well-defined and simple.  Typically a 250 mL Erlenmeyer flask with the chosen 
volume (minimum of 50 mL) of the simulated gastric fluid (0.032N HCl solution at 37 ± 1 °C and 
pH 1.5 ± 0.1) is used. 
There are two distinct applications defined for the test method: 1. grouping and read-across of 
substances and 2. establishing the presence or absence of a matrix effect to inform alloy 
classification. 
Mechanistic Relevance for Application 1:  
It is well-recognised that the systemic toxicity effects of metal-containing materials are related to 
the bioavailability of the metal ion after systemic absorption. The bioelution method measures 
relative bioaccessiblity  and is used as a tool to establish categories of metal-containing materials 
and is part of the WoE approach applied to perform read-across (extrapolation of known data from 
a reference material to a test material based on the assumption that the two materials will cause 
similar biological responses) and grouping.   
Mechanistic Relevance for Application 2:  
Within the EU CLP alloys are considered as mixtures and classified based on their content of 
classified metal (metalloid) ingredients (i.e. the concentration of classified ingredient is compared to 
its classification cut-off value, such as Generic Concentration Limit or Specific Concentration Limit). 
Yet, alloys (composed of more than one metal ingredient) have metallic bonds that can affect metal 
releases in such ways that the bulk concentration of the metal ingredients is not reflected in the 
bioavailability or bioaccessibility of that metal from the alloy (matrix effect), as evidenced by the 
unique physico-chemical properties of alloys. Since the systemic toxicity effects of alloys are related 
to the bioavailable metal ions, it follows that the bioavailability of metals from alloys is not 
expected to match that of a simple mixture. IVBA data from alloy and pure ingredients can be used 
to calculate the %RBC of the metal in the alloy and determine a possible matrix effect of the alloy.  
The bioelution method is representative of the gastric compartment : 
Publications in the peer-reviewed literature show that additional components (e.g., ascorbic acid, 
pepsin, and glycine) could be added to the gastric solution to increase solubility of certain metals 
(e.g., Whitacre et al. 2017). However, these additional components have varying effects on solubility 
for the different metals and add complexity to the method that may lead to extra variability. 
Therefore, the ESAC WG supports keeping the method as simple as possible and acknowledges that 
the simple simulated gastric solution is fit-for-purpose considering the proposed context of use. The 
selection of the 2-hour extraction time is consistent with other IVBA methods using simulated 
gastric fluid and with the time for complete emptying of the human stomach.  
 
5.2 Quality and completeness of the documentation concerning SOPs and 
prediction models 
The SOP is detailed and presents an easy to follow and reproducible method for evaluating the 
relative IVBA of metals in inorganic metal compounds and metal-containing materials such as 
alloys.  Test material and reference materials are always to be run in parallel and the SOP outlines 
which metals are in scope for each of the two applications and how to analyse and make use of the 
relative IVBA (See Section 11.2). 
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6. Test materials 
6.1 Sufficiency of the number of evaluated test items in view of the study 
objective 
The ESAC Working group is satisfied with the number of test items submitted to support the use of 
the Bioelution method for both intended applications. Section 2.2 summarises the studies that were 
conducted with various test materials to validate the method. Testing was conducted on a limited 
number of metals e.g. Co, copper (Cu), iron (Fe), Ni, Pb, zinc (Zn).  However, the ESAC WG considers 
that the Bioelution method should also work for other metals (within the applicability domain of the 
method), especially taking into account that a reference material should always be tested 
concurrently with the tested material.  
 
6.2 Representativeness of the test items with respect to applicability 
The test items were suitable for demonstrating proof-of-concept of both applications of the method.  
Test materials were evaluated at both suggested loadings (0.2 and 2 g/L).  The SOP was amended 
in response to the comments by the ESAC WG.  In order to demonstrate that the change in protocol 
did not change the applicability of the method a subset of test materials were evaluated using both 
preparations of the gastric fluid solution and the results were within the inherent variability of the 
method (as demonstrated by the RRT analysis of the 6 materials within Henderson et al., 2014).  
Annex 2 of the SOP further provides references for each metal included in the applicability domain 
to demonstrate that the various listed metals can be evaluated for bioaccessibility under the test 
parameters (i.e. not anticipated to precipitate, etc.).  
 
 
7. Within-laboratory reproducibility (WLR) (Module 2) 
7.1 Assessment of repeatability and reproducibility in the same laboratory 
The proposed procedure is very simple and easily reproducible. The procedure could be performed in 
the frame of routine laboratory practice of accredited laboratories. The variability between 
replicates is always in the range of introduced criterion for acceptance of the results from the test. 
ESAC agrees that the procedure is fit-for-purpose and the intrinsic data variability is very low. 
 
7.2 Conclusion on within-laboratory reproducibility as assessed by the study 
a) In the RRT study the within-laboratory precision was evaluated calculating the Sr. The 
lowest Sr value was 0.009 (Ni compound) and the highest 0.083 (Fe-Inconel alloy 718). The 
second approach used to assess within-laboratory reproducibility was based on the RSD 
analysis of the log concentration and was expressed in percentages. RSD < 10% was the 
criteria used for acceptable repeatability. All RSD values were below 4%. The highest and 
lowest variability was obtained with Fe-Inconel alloy 718 (3.1%) and Ni compound (0.2%) 
(Henderson et al., 2014). This outcome is consistent with the above Sr approach. The ESAC 
WG considers this to be excellent. 
b) Various experiments with different types of samples (pure metals and alloys) have been 
performed in an accredited laboratory (ECTX) and the within-laboratory repeatability 
assessed is very good with CVs in the range 2-5% for all types of samples, depending only 
on the concentration range. For example, 3% CV for Ni in 0.2 g/L loading and 2% CV in 2 g/L 
loading for Ni (FR X0a-214); 2% CV for Pb and 4% CV for Zn for 0.2 g/L loading for leaded 
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brass (FR X02a-216); 2% CV for Pb in Pb metal for both 0.2 and 2 g/L loadings (FR X0a-
217). 
c) Parallel samples of pure metals and alloys have been analysed in a period of 5 years in the 
same accredited laboratory 2014-2019 (ECTX) [Henderson et al., 2014; (FR X02a-216); (FR 
X0a-217); (FR X02a-229 (ECTX, 2019)]. The calculated RSDs, representing within-laboratory 
reproducibility is up to 10% even after small changes of analytical protocol. These values 
confirmed the sustainability of developed method. 
d) The accredited laboratory ECTX showed consistent results of %RBC for Co in cobalt alloy  (2 
g/L loading) and for Pb in leaded brass alloy (0.2 and 2 g/L  loadings) using two methods of 
HCl pH 1.5 preparation2. This confirms good within-laboratory reproducibility of the 
proposed method for %RBC determination (Summary bioelution tests, 2019). 
 
 
8. Transferability (Module 3) 
8.1 Quality of design and analysis of the transfer phase 
A transferability study was not conducted but the method was implemented in multiple laboratories 
during the RRT and between-laboratory reproducibility data are available. The proposed procedure is 
very simple and easily reproducible. As the procedure will be performed in the frame of routine 
laboratory practice of accredited laboratories, the ESAC WG considers that a transferability study is 
unnecessary. 
 
8.2 Conclusion on transferability to a naïve laboratory / naïve laboratories as 
assessed by the study 
Not applicable. 
 
 
9. Between-laboratory reproducibility (BLR) (Module 4) 
9.1 Assessment of reproducibility in different laboratories 
Five laboratories were used for the RRT, and the results were published in Henderson et al. (2014).   
 
9.2 Conclusion on between-laboratory reproducibility as assessed by the study 
The between-laboratory reproducibility with respect to both, the intrinsic data variability and the 
agreement between laboratories, assessed by RSD and SR:Sr, was considered to be adequate by the 
ESAC WG. 
 
 
 
 
 
                                                 
2 i) A 0.07N HCl solution was prepared and the pH adjusted to 1.5 with NaOH; ii) A HCl dilution to pH 1.5 was 
prepared from a 0.1M HCl titrated solution. 
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10. Predictive capacity and overall relevance (Module 5)  
10.1 Adequacy of the assessment of the predictive capacity in view of the 
purpose 
The Bioelution method is a useful approach for determining the relative IVBA of metal released 
from inorganic metal compounds and metal-containing materials compared to metal released from 
a reference material. The relative IVBA data generated by the Bioelution method can be used to i) 
support grouping and read across and ii) establish the presence or absence of a matrix effect to 
inform alloy classification. Importantly, the Bioelution method is not to be used for predicting 
relative bioavailability for application in a risk assessment context.  
IVBA testing is a well-established approach in use for several years. Bioaccessibility tests for the 
oral route of exposure (including gastric compartment) have been applied to the assessments of 
human exposures to metal compounds and minerals in soils and dust. “It is important to consider 
that while the proposed SOP addresses the generation of IVBA data in simulated gastric fluid and 
its use for the calculation of the %RBC of metals in alloys, how this will be used in a regulatory 
context is not part of the SOP.” A comparison of the relative IVBA data with in vivo relative 
bioavailability data was not conducted in this ESAC review. Relative bioavailability is the ratio of the 
oral absorption fraction of the chemical present in some target material to the oral absorption 
fraction of the chemical in an appropriate reference material as measured in an animal model. It 
accounts for differences in absorption between the chemical in the reference material and in the 
test material. Such comparison is not necessary and does not compromise the assessment of the 
scientific validity of the method given that relative measurements between target and reference 
materials are used both for grouping and read across, and classification of alloys. The lack of in 
vivo bioavailability to support the results of the IVBA analysis is considered a significant limitation 
of the method and prevents the ESAC WG from recommending the direct use of bioelution data in 
human health risk assessments.   
 
10.2 Overall relevance (biological relevance and accuracy) of the test method in 
view of the purpose 
The Bioelution method is an in vitro method used to measure metal releases in simulated gastric 
fluid (pH 1.5). It does not address a biological effect. The Bioelution method provides data regarding 
relative IVBA, and it is important to consider that bioaccessibility is related to systemic 
bioavailability of metal ions (see section 2.1). 
 
 
11. Applicability domain (Module 6)  
11.1 Appropriateness of study design to conclude on applicability domain, 
limitations and exclusions 
ESAC WG considers that the information provided on the applicability domain and the limitations of 
the test method is appropriate.  
 
11.2 Quality of the description of applicability domain, limitations, exclusions 
The applicability domain is clearly described in the SOP in terms of technical limitations and context 
of use and is considered appropriate. Reproducibility and international harmonisation are ensured by 
clearly defining the reference materials for each metal that must be run in parallel to test materials 
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for alloy classification purposes. While for the read across and grouping application it is not possible 
to predefine the reference materials, the SOP still requires these to be run concurrently to the target 
material so as to guarantee the robustness and consistency of the relative measurement. Table 1 
outlines which metals/metalloids are within scope for each of the two applications; the references 
for this table are provided in Annex 2 of the SOP. In conclusion, the ESAC considers that the SOP is 
well described and robust, thus ensuring reproducibility of data and easy implementation of the 
assay by naïve laboratories. 
 
Table 1. Metal/Metalloid within and out of scope of main two applications  
Metal/metalloid Simulated gastric fluid 
technical applicabilitya 
Application 1b Application 2c 
Ag NA NA NA 
Ag compounds NA NA NA 
As          
As compounds   NR 
Au   NC 
B   NC 
B compounds   NR 
Be pending d 
 
 d  d 
Cd    
Cd compounds   NR 
Co    
Co compounds   NR 
Cr   NC 
Cr compounds   NR 
Cu   NC 
Cu compounds   NR 
Fe   e NC 
Fe compounds   NR 
Ge   NC 
Ge compounds   NR 
Hg NA NA NA 
Hg compounds NA NA NA 
In   NC 
In compounds   NR 
Mn   NC 
Mn compounds   NR 
Mo   NC 
Mo compounds  e NR 
Ni    
Ni compounds   NR 
Pb    
Pb compounds   NR 
Pd   NC 
Pd compounds   NR 
Pt   NC 
Re   NC 
    
Rh   NC 
Rh compounds   NR 
Ru   NC 
Sb   NC 
Sb compounds  f e NR 
Se pending d   d  d 
Si  e NC 
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Si compounds   NR 
Ti   NC 
Ti compounds   NR 
V   NC 
V compounds   NR 
W  e NC 
W compounds   NR 
Zn   NC 
Zn compounds   NR 
Zr   NC 
a A check mark means that the element can be measured in simulated gastric fluid without technical 
limitations (e.g. no precipitation, no complexation). b A check mark means that the element is within scope of 
grouping and read across. c A check mark means that the element is within scope of calculating %RBC to 
inform alloy classification for oral route. d Testing their applicability in simulated gastric fluid will be 
addressed as part of the proposed testing of Reference Materials, see Annex 1 of the SOP. e Element release 
in simulated gastric fluid is not a worst-case scenario for the oral route and additional information is needed. 
See examples in text above table. f Except Antimony trichloride (ATC) and Antimony pentachloride (APC) and 
any other corrosive Sb compounds.   
 
NA: not applicable; NR: Not relevant as metal compounds are not the primary references for the calculation of 
relative bioaccessible concentration (%RBC) in alloys; NC: the metal/metalloid (Metalo) is not currently 
classified for systemic effects and therefore it is outside of the scope of application . 
 
 
12. Performance standards (Module 7)  
Performance Standards are not considered necessary due to the fact that the test method has no 
proprietary elements. 
 
12.1 Adequacy of the proposed Essential Test Method Components 
Not applicable. 
 
12.2 Adequacy of the proposed Reference Chemicals 
Not applicable. 
 
12.3 Adequacy of the proposed performance target values 
Not applicable. 
 
 
13. Readiness for standardised use 
13.1 Assessment of the readiness for regulatory purposes 
The ESAC WG considers the Bioelution method to be ready for standardised use in a regulatory 
context to i) support grouping and read across and ii) establish the presence or absence of a matrix 
effect to inform alloy classification. However, the exact manner in which the relative IVBA data 
generated with the simulated gastric fluid will be used in a regulatory context was not part of the 
present  assessment. 
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13.2 Assessment of the readiness for other uses  
The available information did not permit the assessment of the validity of the Bioelution method to 
predict relative bioavailability values for application in a risk assessment context.   
 
13.3 Critical aspects impacting on standardised use 
The following factors should be taken into consideration to guarantee a standardised use of the 
Bioelution test method: 
• Standardised materials (i.e. proficiency materials and reference materials) should be 
available for testing by laboratories using the gastric Bioelution test SOP. 
• The test material should always be run in parallel to a reference material.  
• Same reference materials need to be used across laboratories to establish the presence or 
absence of a matrix effect in alloys and to calculate the RBC%  of the metal in the alloy. 
• For the alloys, the reference material and the test material should have similar physical 
form. 
• Acceptance criteria for the proficiency materials need to be established. 
• A physical repository of proficiency materials and the reference materials for the alloys and 
a publically available database to housing measurements of the samples present in the 
repository need to be established. 
 
13.4 Gap analysis 
All gaps identified were addressed with the test method submitter during the peer-review process. 
These were considered to be addressed before issuing the present assessment report and the ESAC 
Opinion. The main points addressed are listed here below. 
General: 
- Clarify the proposed applications i) grouping and read-across and ii) alloy classification. 
- Ensure using the wording ‘relative’ bioaccessible concentration throughout the documents. 
- Clarify the rationale for the proposed gastric fluid composition. 
- Clarify the applicability domain of the test method. 
Procedural: 
- Make use of a simplified preparation of the gastric fluid. 
- Clarify in the SOP the need to run in parallel the testing reference materials and indicate the 
selection criteria of these reference chemicals. 
- Commitment from test submitter to set up a repository of reference materials. 
- Proof-of-concept testing that demonstrate the revised SOP provide reproducible results. 
Standard Operating Procedure: 
- Clarifications regarding homogeneity of the test samples. 
- Clarifications regarding the data interpretation procedure. 
- Use of a confidence interval for the %RBC. 
- Clarifications on how to select the release data from high or low loading for each application. 
- Clarifications on when epoxy embedded sample can be used. 
- Clarify the procedures to be undertaken in case of pH drift. 
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14. Other considerations 
No other considerations were addressed by the ESAC WG. 
 
 
15. Conclusions on the study 
15.1 ESAC WG summary of the results and conclusions of the study 
In vivo oral bioavailability refers to the fraction of the total amount of a substance that is released 
in the gastrointestinal tract and absorbed into the blood stream. This can be estimated in vitro by 
measuring the dissolved quantity of a metal ion release under surrogate physiological condition in a 
bioaccessibility test.  
The Bioelution method generates relative IVBA data that may be used as supportive information for 
(i) classification of inorganic metal compounds and metal-containing materials (e.g. UVCBs, 
pigments and alloys) by grouping and read across and (ii) classification of alloys, where the %RBC 
of a metal in an alloy versus a reference material (e.g. a pure metal) is used to establish the 
presence or absence of a matrix effect. 
A comparison of the IVBA data with in vivo oral relative bioavailability data was not conducted in 
this ESAC review. Relative bioavailability is the ratio of the oral absorption fraction of the chemical 
present in some target material to the oral absorption fraction of the chemical in an appropriate 
reference material. It accounts for differences in absorption between the chemical in the reference 
material and in the test material. Such comparison is not necessary and does not compromise the 
assessment of the scientific validity of the method given that relative measurements between 
target and reference materials are used both for grouping and read across, and classification of 
alloys. 
 
15.2 Extent to which study conclusions are justified by the study results alone 
The Bioelution method can be used to assess the matrix effect of an alloy by comparing the release 
of metal ions between a reference material (e.g. pure metal) and an alloy. When a matrix effect 
occurs, there is an increased or decreased relative release of the metal ions from the alloy in 
comparison to the reference material. In the absence of a matrix effect (e.g. simple metal mixture), 
a linear relationship between the fraction of metal ion release and the total content of that metal in 
the material is expected and this has been confirmed by the method submitter. Therefore, the ESAC 
considers that this is an appropriate use of the Bioelution method. 
ESAC considers that the within- and between-laboratory reproducibility of absolute bioaccessibility 
measurements for the six metals tested (i.e. Co, Cu, Fe, Ni, Pb, Zn tested in the RRT as published by 
Henderson et al., 2014) were acceptable. The ESAC considers that this should hold true also for 
other metals; however, data have not been provided to support this assumption. The current SOP 
further ensures reproducibility across laboratories by ensuring high consistency in the preparation 
of the simulated gastric fluid. Reproducibility and international harmonisation are also ensured by 
clearly defining the reference materials for each metal that must be run in parallel to test materials 
for alloy classification purposes. While for the read across and grouping application it is not possible 
to predefine the reference materials, the SOP still requires these to be run concurrently to the target 
material so as to guarantee the robustness and consistency of the relative measurement.  
The applicability domain is clearly described in the SOP in terms of technical limitations and context 
of use and is considered appropriate. In conclusion, the ESAC considers that the Bioelution method 
is well described and robust, thus ensuring reproducibility of data and easy implementation of the 
assay by naïve laboratories. 
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15.3 Extent to which conclusions are plausible in the context of existing 
information 
The Bioelution method is representative of the gastric compartment. Publications in the peer-
reviewed literature show that additional components (e.g., ascorbic acid, pepsin, and glycine) could 
be added to the gastric solution to increase solubility of certain metals (e.g., Whitacre et al. 2017). 
However, these additional components add complexity to the method and are unlikely to affect the 
relative measurement that the method produces. The selection of the 2-hour extraction time is 
consistent with other IVBA methods using simulated gastric fluid and with the time for complete 
emptying of the human stomach. The ESAC supports the current Bioelution method protocol and 
acknowledges that the simple gastric solution is fit-for-purpose considering the proposed context of 
use. 
IVBA testing is a well-established approach in use for several years. Bioaccessibility tests for the 
oral route of exposure (including gastric compartment) have been applied to the assessments of 
human exposures to metal compounds and minerals in soils and dust. US EPA Validated Test 
Method 1340 assesses the bioaccessibility for Pb in soil. Validation studies of IVBA test methods for 
estimation of bioavailability of As from soil and sediment have been conducted. Moreover, the 
proposed Bioelution method is similar to the Bioaccessibility Research Group of Europe (BARGE) 
method, which has been in use in Europe for several years to assess As, Pb, Sb and Cd in soil 
samples and was accepted as an ISO standard in 2018 (ISO 17924). 
 
 
16. Recommendations 
16.1 General recommendations 
The ESAC WG concludes that the Bioelution method is scientifically valid for determining the 
relative IVBA of metals in inorganic metal compounds and metal-containing materials. Furthermore, 
the ESAC WG recommends that the Bioelution method progresses to Test Guideline development at 
OECD level to achieve international harmonisation. The development of a standardized and agreed 
test guideline will be helpful to ensure the protocol of the Bioelution method is applied consistently 
across jurisdictions. 
 
16.2 Specific recommendations (e.g. concerning improvement of SOPs) 
Specific recommendations were addressed during the peer-review process and are described in 
section 13.4. The only pending action remains the set-up of a repository of reference materials. 
 
 
 
 
 
 
 
 
 
ANNEX 2 - ESAC WORKING GROUP REPORT  Page | 29 
17. References 
• Alloy LLC. 2017. Bioavailability of Metals from Soil: Review of In Vitro Methods to Predict 
RBA (unpublished).  
• BARGE. 2016. The BARGE unified bioaccessibility method. The Bioaccessibility Research 
Group of Europe. https://www.bgs.ac.uk/barge/ubm.html. 
• Brattin W, Drexler J, Lowney Y, Griffin S, Diamond G, Woodbury L. 2013. An in vitro 
methodfor estimation of arsenic relative bioavailability in soil. J Toxicol Environ Health Part 
A 76: 458-478. 
• BS (British Standard) EN 71–3. 2013. Safety of toys. Migration of certain elements. Cordeiro 
F, Baer I, Robouch P, Emteborg H, Got JC, Kortsen B, de la Calle B. 2012. IMEP-34: Heavy 
metals in toys according to EN 71–3:1994; Interlaboratory Comparison Report. JRC Scientific 
and Policy Reports. EUR 25380 EN. 
• ESTCP. 2012. Validation of an In Vitro Bioaccessibility Test Method for the Estimation of the 
Bioavailability of Arsenic from Soil and Sediment Cost and Performance Report 
Environmental Security Technology Certification Program U.S. Department of Defense (ER-
200916). 
• Henderson R, Verougstraete V, Anderson K, Arbildua JJ, Brock TO, Brouwers T, Cappellini D, 
Delbeke K, Herting G, Hixon G, Wallinder IO, Rodriguez PH, Assche FV, Wilrich P, Oller AR. 
2014. Interlaboratory validation of bioaccessibility testing for metals. Reg Toxicol Pharmacol 
70:170-181. 
• Henderson RG, Cappellini D, Seilkop SK, Bates HK, Oller AR. 2012. Oral bioaccessibility 
testing and read-across hazard assessment of nickel compounds. Regul Toxicol Pharmacol 
63: 20–28.  
• OECD. 2001. OECD Series on Testing and Assessment Number 29. Guidance Document on 
Transformation/Dissolution of Metals and Metal Compounds in Aqueous Media. 
ENV/JM/MONO(2001)9.  
• Ruby MV, Schoof R, Brattin W, Goldade M, Post G, Harnois M, Mosby DE, Casteel SW, Berti W, 
Carpenter M, Edwards D, Cragin D, Chappell W. 1999. Advances in Evaluating the Oral 
Bioavailability of Inorganics in Soil for Use in Human Health Risk Assessment. Env Sci and 
Technol 33: 3697–3705. 
• Stopford W, Turner J, Cappellini D, Brock T. 2003. Bioaccessibility testing of cobalt 
compounds. J Environ Monit 5: 675–680. 
• Suh M, Casteel S, Dunsmore M, Ring C, Verwiel A, Proctor DM. 2019. Bioaccessibility and 
relative oral bioavailability of cobalt and nickel in residential soil and dust affected by metal 
grinding operations. Sci Tot Environ 660:677–689. 
• Whitacre SD, Basta NT, Stevens BN, Hanley V, Anderson RH, Scheckel KG, Foster AL. 2017 
Modification of an existing in vitro method to predict relative bioavailable arsenic in soil. 
Chemosphere 180: 545-552. 
• Wragg J, Cave M, Basta N, Brandon E, Casteel S, Denys S, Gron C, Oomen A, Reimer K, Tack 
K, Van de Wiele T. 2011. An inter-laboratory trial of the unified BARGE bioaccessibility 
method for arsenic, cadmium and lead in soil. Sci Total Environ 409: 4016–4030. 
 
 
 
EUROPEAN COMMISSION 
DIRECTORATE-GENERAL 
JOINT RESEARCH CENTRE 
Directorate F - Health, Consumers and Reference Materials 
European Union Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) 
 
ANNEX 2 - ESAC WORKING GROUP REPORT         Page | 30 
Appendix 1. Overview of the tests performed at ECTX laboratories during Submission/review of the 
Bioelution Test Method 
 
FR X02a-081 
(18/06/2017) 
Exp. starting date: 11-11-2016  
Exp. completion date: 05-12-
2016  
2 hours Bio-elution Study on 
Stainless Steel 316L Massive 
(Epoxy resin embedded) 
at a 2 g/L loading (surface equivalent) 
in a simulated gastric fluid 
No reference materials tested in 
parallel   
 
Co release: 0.063 µg/g ± 
0.003  
Ni release: 1.55 µg/g ± 
0.08 
FR X02a-084 
(18/06/17) 
Exp. starting date: 11-11-2016  
Exp. completion date: 05-12-
2016 
2 hours Bio-elution Study on Stainless Steel 
316L Powder at a 2 g/L loading in a 
simulated gastric. 
Cobalt (content: ≤0.214 %), nickel (content: 
10.65 %) 
No reference materials tested in 
parallel 
Co release: 2.91 µg/g ± 
0.04 
Ni release: 61.4 µg/g ± 0.3 
FR X02a-130 
(19/12/17) 
Exp. starting date: 19-09-2017 
Exp. completion date: 22-09-
2017  
 
2 hours Bio-elution Study on Fe-Cr-Ni 
Powder Mixture (68.6/16.4/10.7 mass 
fraction) at a 0.2, 1 and 2 g/L loading in a 
simulated gastric fluid 
Reference materials tested: Cr, Fe, 
Ni powders tested at 0.2g/L 
loading 
• To demonstrate presence 
of a matrix effect in 
alloys. See Table 7 in 
“Responses to questions in 
EURL ECVAM Test 
Presubmission Assessment 
Report”. 
• To examine the influence 
of sample mass, either 
as inert material (SiO2) or 
as alloy material on the 
release of Ni. See Table 8 
in “Responses to questions 
in EURL ECVAM Test 
Presubmission 
Assessment Report”. 
FR X02a-144 
(21/04/18) 
 
Exp. starting date: 24-01-2018  
Exp. completion date: 02-02-
2018  
 
 
2 hours Bio-elution Study on Stainless Steel 
316L Powder at a 2 g/L loading in a 
simulated gastric fluid. Cobalt (content: 
≤0.214 %), nickel (content: 10.65 %) 
Three reference materials tested: 
Nickel powder with a comparable 
amount of nickel(nominal loading 
0.2g/L) 
Nickel powder (nominal loading 
0.2g/L) supplemented with an inert 
material (silicon dioxide) up to a 
final loading of 2g/L 
Silicon dioxide (1.79 g/L) 
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FR X02a-145 
(21/04/18) 
Exp. starting date: 24-01-2018 
Exp. completion date: 02-02-
2018  
 
4 hours Bio-elution Kinetics Study on 
Stainless Steel 316L Powder at a 2 g/L 
loading in a simulated gastric fluid. 
Nickel (content 10.65 % 
Iron (content 68.61 %) 
An alloy (SS316L), two of its pure ingredients 
(Feo and Nio) and two water soluble 
compounds of these metal ingredients (FeSO4 
7H2O and NiCl2 6H2O) were tested 
Reference materials: 
2 g/L nickel powder 
2 g/L loading of nickel(II)chloride 
hexahydrate 
2 g/L iron powder 
2 g/L loading of iron(II) sulfate 
heptahydrate  
 
To examine the kinetics 
of metal release in gastric 
fluid.  
See Figure 7 in “Responses 
to questions in EURL ECVAM 
Test Presubmission 
Assessment Report”. 
FR X02a-146 
(21/04/18) 
Exp. starting date: 24-01-2018  
Exp. completion date: 02-02-
2018  
 
 
4 hours Bio-elution Kinetics Study on Z45 
(massive) at a 2 g/L loading (surface 
equivalent) in a simulated gastric fluid  
 
An alloy (Z45, 62.176% copper) and its pure 
ingredient (Cuo, 100% Cu), both as disks, were 
tested 
Reference material: copper 
massive 
To examine the kinetics 
of metal release in gastric 
fluid (massive sample). 
See Figure 8 in “Responses 
to questions in EURL ECVAM 
Test Presubmission 
Assessment Report”. 
FR X02a-213 
(09/10/19)  
Exp. starting date: 22-07-2019  
Exp. completion date: 02-08-
2019  
 
2 hours Bioelution Study on Nickel sulfate 
hexahydrate at a 0.2 and 2 g/L loading in a 
simulated gastric fluid 
 Comparability of 
bioelution results obtained 
with three nickel compounds 
tested in 2009 (reported in 
Henderson et al., 2012) and 
with current SOP (pH 
simulated gastric fluid 
adjusted with NaOH) 
See Table 3 in Annex 1 to 
responses to ESAC 
comments – “Annex 1 RCOM 
24092019” (Summary of 
bioelution tests performed 
to address 
questions/concerns raised by 
ESAC). 
FR X02a-214 
(09/10/19) 
Exp. starting date: 22-07-2019  
Exp. completion date: 02-08-
2019  
 
2 hours Bioelution Study on Nickel 
subsulfide at a 0.2 and 2 g/L loading in a 
simulated gastric fluid 
 
FR X02a-215 
(09/10/19) 
Exp. starting date: 22-07-2019  
Exp. completion date: 02-08-
2019  
 
2 hours Bioelution Study on Nickel oxide at 
a 0.2 and 2 g/L loading in a simulated gastric 
fluid 
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FR X02a-216 
09/10/19) 
Exp. starting date: 22-07-2019  
Exp. completion date: 02-08-
2019  
 
2 hours Bioelution Study on Leaded Brass 
Alloy at a 0.2 and 2 g/L loading in a 
simulated gastric fluid 
(58.45% Cu, 3.22% Pb, 37.75 % Zn) 
 
Leaded brass alloy used in 
Henderson et al., 2014 
 
Comparability of 
bioelution results with 
those obtained in round 
robin (Henderson et al., 
2014). See Table 2 in Annex 
1 to responses to ESAC 
comments – “Annex 1 RCOM 
24092019” (Summary of 
bioelution tests performed 
to address 
questions/concerns raised by 
ESAC). 
 
Calculate the RBC% of Pb 
in leaded brass alloy. 
Consider data from both 
loadings. See Table 5 in 
Annex 1 to responses to 
ESAC comments – “Annex 1 
RCOM 24092019” 
(Summary of bioelution 
tests performed to address 
questions/concerns raised by 
ESAC). 
FR X02a-217 
(09/10/19) 
Exp. starting date: 22-07-2019  
Exp. completion date: 02-08-
2019  
 
2 hours Bioelution Study on Lead (powder) 
at a 0.2 and 2 g/L loading in a simulated 
gastric fluid 
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FR X02a-218 
(09/10/19) 
Exp. starting date: 22-07-2019  
Exp. completion date: 02-08-
2019  
 
2 hours Bioelution Study on Cobalt (powder) 
at a 0.2 and 2 g/L loading in a simulated 
gastric fluid 
Co metal powder used in 
Henderson et al., 2014 
Comparability of 
bioelution results with 
those obtained in round 
robin (Henderson et al., 
2014). See Table 2 in Annex 
1 to responses to ESAC 
comments – “Annex 1 RCOM 
24092019” (Summary of 
bioelution tests performed 
to address 
questions/concerns raised by 
ESAC). 
FR X02a-219 
(09/10/19) 
Exp. starting date: 22-07-2019  
Exp. completion date: 02-08-
2019  
 
2 hours Bioelution Study on Cobalt (powder) 
at a 0.2 and 2 g/L loading in an alternative 
prepared simulated gastric fluid 
 Comparison of metal 
release using simulated 
gastric fluid prepared in 
two different ways: a) 
from 0.07 N HCl adjusted to 
pH 1.5 with NaOH or b) as a 
diluted of a concentrated 
HCl solution. See Table 4 in 
Annex 1 to responses to 
ESAC comments – “Annex 1 
RCOM 24092019” 
(Summary of bioelution 
tests performed to address 
questions/concerns raised by 
ESAC). 
FR X02a-220 
(09/10/19) 
Exp. starting date: 11-08-2019  
Exp. completion date: 16-08-
2019  
 
2 hours Bioelution Study on Lead (powder) 
at a 0.2 and 2 g/L loading in an alternative 
prepared simulated gastric fluid 
 
FR X02a-229 
(11/12/19) 
Exp. starting date: 10-10-2019 
Exp. completion date: 22-10-
2019  
 
2 hours Bioelution Study on Leaded Brass 
Alloy at a 0.2 and 2 g/L loading in a 
simulated gastric fluid  
 
Leaded brass alloy powder used in Henderson 
et al 2014 and in X02a-2016 
Leaded brass alloy powder used in 
Round Robin (Henderson et al., 
2014) and in previous studies 
(X02a-216) 
Calculation of %RBC of 
lead in leaded brass, at 
two loadings, and with two 
methods of HCl pH 1.5 
preparation. See Tables 2 
and 3 in “Results of Oct 
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FR X02a-230 
(11/12/19) 
Exp. starting date: 10-10-2019 
Exp. completion date: 22-10-
2019  
 
2 hours Bioelution Study on Lead (powder) 
at a 0.2 and 2 g/L loading in a simulated 
gastric fluid 
Pb metal powder used in previous 
studies (X02a-220) 
2019 testing” (Summary of 
bioelution tests performed 
to address 
questions/concerns raised by 
ESAC). 
FR X02a-231 
(11/12/19) 
Exp. starting date: 10-10-2019 
Exp. completion date: 22-10-
2019  
 
2 hours Bioelution Study on Cobalt (powder) 
at a 2 g/L loading in a simulated gastric fluid 
Cobalt metal powder Calculation of %RBC of 
cobalt in a cobalt alloy, at 
the high loading of 2 g/L, 
and with two methods of 
HCl pH 1.5 preparation. See 
Tables 4 and 5 in “Results of 
Oct 2019 testing” (Summary 
of bioelution tests 
performed to address 
questions/concerns raised by 
ESAC). 
FR X02a-232 
(11/12/19) 
Exp. starting date: 10-10-2019 
Exp. completion date: 22-10-
2019  
 
2 hours Bioelution Study on Cobalt alloy 
(powder) at a 2 g/L loading in a simulated 
gastric fluid 
Cobalt alloy 
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